Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss

Fig. 3

SIRT3 is a target of miR-6359 during osteoclastogenesis. a Venn diagram showing the miR-6359 targets from miRWalk, TargetScan, miRDB database and OP-related genes. b qRT-PCR analysis of suspected miR-6359 targets (SIRT3, SET, WWTR1 and DMD) (n = 3 or 4). c Western blot quantification of SIRT3 expression level in osteoclast precursors with indicated treatments. d qRT-PCR analysis of SIRT3 expression level in osteoclast precursors with different treatment (n = 4). e Alignment between miR-6359 with the 3’ UTR of SIRT3 showing potential binding sites. f SIRT3 wild-type and mutant cell luciferase activity after transfection with agomiR-6359 or agomiR-NC (n = 4). g, h Immunofluorescence staining and quantitative analysis of SIRT3 in femoral sections of mice treated with vehicle or VPA (n = 3). Scar bar: 20 μm. i, j Immunofluorescence staining and quantification of SIRT3 in osteoclast precursors with indicated treatments (n = 3). Scar bar: 100 μm. k, l CX3CR1+, Csf1R+ osteoclast precursors were sorted by flow cytometry (k) and qRT-PCR analysis was used to detect the expression level of SIRT3 (l) (n = 5). Data are presented as the mean ± SEM (n ≥ 3) (*p < 0.05; **p < 0.01; ***p < 0.001)

Back to article page